P86.F Paradigm Biopharmaceuticals Limited

Healthcare Biotechnology Frankfurt Exchange
0.1500 EUR
Close of Nov 12, 2026
0.0815 0.2060
Market cap
EUR 94.0M
P/E
-
P/B
43.94x
ROE
-1,623.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is P86.F undervalued?

Graham number

The Graham number of Paradigm Biopharmaceuticals Limited cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Paradigm Biopharmaceuticals Limited fundamental analysis

No fundamental analysis for Paradigm Biopharmaceuticals Limited yet.

Paradigm Biopharmaceuticals Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Paradigm Biopharmaceuticals Limited

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.

Full company profile